Active Ingredient History
Encenicline is a selective partial agonist of the α7 nicotinic receptor. It was in phase III clinical trials for the treatment of cognitive impairment in schizophrenia, but failed to meet the study endpoints in 2016. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alzheimer Disease (Phase 3)
Central Nervous System Diseases (Phase 2)
Cognition (Phase 2)
Cognition Disorders (Phase 3)
Dementia (Phase 3)
Healthy Volunteers (Phase 1)
Heart Diseases (Phase 1)
Kidney Failure, Chronic (Phase 1)
Liver Diseases (Phase 1)
Psychotic Disorders (Phase 1)
Schizophrenia (Phase 3)
Smoking Cessation (Phase 2)
Tobacco Use Disorder (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue